Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
13
Recruiting, industry sponsors, Neurology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed274
13 trials
Showing 1 to 13, recently updated first.
PfizerPfizer (PFE)
NCT07609914 · 400 participants (planned) · Start May 28, 2026 · Primary completion Jun 7, 2028
Drug: Rimegepant · For: Acute Treatment of Migraine
Sites: Canoga Park, California; Fresno, California; Los Angeles, California · 38 sites in all
PfizerPfizer (PFE)
NCT07685769 · 60 participants (planned) · Start Jul 24, 2026 · Primary completion Jan 4, 2028
Drug: Rimegepant 75 mg ODT · For: Acute Treatment of Migraine
Sites: Visakhapatnam, India; Gurugram, India; Bangalore, India · 7 sites in all
argenxargenx (ARGX)
NCT06909214 · 35 participants (planned) · Start Apr 17, 2025 · Primary completion Jul 8, 2026
Drug: Efgartigimod PH20 SC · For: New Onset Generalized Myasthenia Gravis (gMG)
Sites: La Jolla, California; Rancho Mirage, California; Boca Raton, Florida · 18 sites in all
Eidos Therapeutics, a BridgeBio companyIndustry
NCT07695701 · 150 participants (planned) · Start Jul 28, 2026 · Primary completion Aug 2030
Drug: Acoramidis (AG10) oral tablet · For: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloidosis; Amyloid Cardiomyopathy and 1 more
Sites: Baltimore, Maryland; St Louis, Missouri; Philadelphia, Pennsylvania · 9 sites in all
Alpha Cognition, IncIndustry
NCT07633470 · 150 participants (planned) · Start May 20, 2026 · Primary completion Apr 2027
Drug: Zunveyl® · For: Alzheimer Disease
Sites: Irvine, California; Orange, California; Aventura, Florida · 26 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07609719 · 100 participants (planned) · Start Sep 2, 2026 · Primary completion Feb 28, 2029
Drug: OCR SC · For: Multiple Sclerosis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Fort Collins, Colorado · 8 sites in all
- A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in FinlandPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07502560 · 33,609 participants (planned) · Start Mar 31, 2026 · Primary completion Apr 1, 2030
Drug: Recombinant zoster vaccine; Placebo · For: Herpes Zoster
Sites: Espoo, Finland; Helsinki, Finland; Jarvenpaa, Finland · 8 sites in all
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT07221838 · 75 participants (planned) · Start Mar 4, 2026 · Primary completion Aug 27, 2027
Drug: Ravulizumab; Prednisone/Prednisolone · For: Generalized Myasthenia Gravis; gMG
Sites: Chicago, Illinois; Schaumburg, Illinois; Neptune City, New Jersey · 12 sites in all
- Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.Pivotal-lookingRecruiting
Royal BiologicsIndustry
NCT07209475 · 248 participants (planned) · Start Aug 14, 2025 · Primary completion Aug 14, 2026
Drug: Amnio-Maxx® Dual Layer Amnion Patch · For: Diabetic Foot Ulcer (DFU); Amnio-Maxx
Sites: Burbank, California; Miami, Florida; Stone Mountain, Georgia · 8 sites in all
Impax Laboratories, LLCIndustry
NCT06765668 · 220 participants (planned) · Start Feb 12, 2025 · Primary completion Nov 2025
Drug: CREXONT ER · For: Parkinson Disease
Sites: Phoenix, Arizona; Little Rock, Arkansas; Aliso Viejo, California · 27 sites in all
Qilu Pharmaceutical Co., Ltd.Industry
NCT06940336 · 15 participants (planned) · Start Jun 19, 2025 · Primary completion Jan 2028
Drug: Tafamidis Meglumine Soft Capsules · For: Transthyretin Amyloid Polyneuropathy
Sites: Jinan, China
- Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years OldPivotal-lookingRecruiting
Upsher-Smith LaboratoriesIndustry
NCT04748601 · 132 participants (planned) · Start Feb 19, 2021 · Primary completion Sep 2026
Drug: Qudexy XR; Placebo · For: Migraine Disorders
Sites: Birmingham, Alabama; La Jolla, California; Aurora, Colorado · 15 sites in all
- An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's DiseasePivotal-lookingRecruiting
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.Industry
NCT05908695 · 1,312 participants (planned) · Start Aug 31, 2023 · Primary completion Jun 2029
Drug: GV-971; Placebo · For: Alzheimer's Disease
Sites: Huainan, China; Beijing, China; Xiamen, China · 50 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.